PDCT-02. COMBINED INHIBITION OF MTORC1/C2 AND MEK PATHWAY IS SYNERGISTIC IN PRECLINICAL TESTING OF PEDIATRIC LOW-GRADE GLIOMA INCLUDING A NOVEL PATIENT-DERIVED NF1 PILOCYTIC ASTROCYTOMA CELL LINE

Documenti analoghi

• LGG-52. DUAL INHIBITION OF mTORC1/C2 AND MEK PATHWAY IS SYNERGISTIC IN MULTIPLE HUMAN MODELS OF PEDIATRIC LOW-GRADE GLIOMA INCLUDING A NOVEL PATIENT-DERIVED NF1 PILOCYTIC ASTROCYTOMA CELL LINE
  di: Arnold, Antje, et al.
  Pubblicazione: (2018)
• LGG-13. SYNERGISTIC TREATMENT FOR PEDIATRIC LOW GRADE GLIOMA WITH THE DUAL MTORC1/2 INHIBITOR TAK-228 AND MEK INHIBITOR TRAMETINIB
  di: Arnold, Antje, et al.
  Pubblicazione: (2017)
• Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity
  di: Arnold, Antje, et al.
  Pubblicazione: (2020)
• Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target
  di: Hütt-Cabezas, Marianne, et al.
  Pubblicazione: (2013)
• EPID-02 AN UNUSUAL PEDIATRIC HYPOTHALAMIC PILOCYTIC ASTROCYTOMA
  di: Rumler, Sarah, et al.
  Pubblicazione: (2015)